

## Prominex raises \$6m in Series B fundraising

Funding development of 5-minute point-of-care molecular diagnostics

**May 31, 2019**

San Diego, CA, May 31, 2019 – Prominex, Inc., a molecular diagnostic company focused on point-of-care infectious disease testing, today announces completion of its Series B financing, raising \$6 million from [Casdin Capital LLC](#) and its founding CEO. The Series B financing will provide funding to advance the development of its infectious disease assays and commence an instrument development partnership with [Invetech](#), a global leader in point-of-care instrument design and development.

Prominex's Founder and CEO Paul Thomas commented, "Our Validex System delivers a 5-minute sample-to-answer molecular test result that will enable a broad spectrum of point-of-care testing from simple screening to more complex syndromic panel assays. We believe our Validex System holds significant promise to improve patient care and outcomes in time-critical clinical situations and to realize significant cost savings by optimized patient management and triage of patients to the most appropriate care setting."

### **About Prominex**

Prominex was founded in 2017 with a primary focus on the development of molecular diagnostic assays for point-of-care infectious disease testing. The novel molecular amplification and waveguide detection technologies incorporated into our Validex System enables the development of ultra-fast, accurate, easy-to-use, highly multiplexed, and low-cost molecular diagnostic assays. For more information, visit [www.Prominex.com](http://www.Prominex.com)

### **Contact**

Paul E. Gargan  
(858) 242-1541  
[pgargan@prominex.com](mailto:pgargan@prominex.com)